| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 6.9 | 14.3 |
| Net income | -12.4 | -0.3 |
| EPS (diluted, $ a share) | $-0.58 | $-0.03 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -51.8% |
|---|---|
| Operating margin | -176.0% |
10-Q filed with the SEC, NASDAQ: VRCA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Verrica Pharmaceuticals Inc.: key numbers
- Share price
- $3.20Close, Nov 16
- Market cap
- $55M
- Shares outstanding
- 17.18MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Verrica Pharmaceuticals Inc.
All →Verrica Pharmaceuticals Financial Results
Verrica Pharmaceuticals reported record Q3 2026 YCANTH net product revenue of $5.7 million, a 57.9% increase year-over-year, and total revenue of $6.9 million. The company completed enrollment in its first Phase 3 pivotal trial for common warts and unlocked $27.5 million in non-dilutive growth capital by meeting credit facility milestones.
- Term
- Q3 2026
“Verrica made progress in growing our commercial YCANTH business for molluscum contagiosum while advancing our late-stage pipeline for two of the most prevalent skin diseases, and extending our cash runway during the third quarter.”
Jayson Rieger, PhD, MBA, President and Chief Executive Officer
“Under our current operating plan, including finishing the global Phase 3 program in common warts, and the full utilization of our credit facility, we now have sufficient liquidity to fund operations through data readouts for both pivotal trials of the common warts program.”
Jayson Rieger, PhD, MBA, President and Chief Executive Officer